Lung Carcinoid Tumor
Associated Genetic Biomarkers
NCI Definition: A neuroendocrine neoplasm that arises from the lung. It is characterized by the presence of uniform polygonal cells with small or moderate amount of cytoplasm and inconspicuous nucleoli. The cells are usually arranged in organoid and trabecular patterns. It is classified as typical or atypical carcinoid tumor based on the number of mitotic figures and the absence or presence of necrosis. Atypical carcinoid tumors have a worse prognosis. 
Lung carcinoid tumors most frequently harbor alterations in MEN1, ARID1A, EIF1AX, ATM, and CCND1 .
EIF1AX Mutation, MEN1 Mutation, ATM Mutation, ARID1A Nonsense, and ARID1A Mutation are the most common alterations in lung carcinoid tumor .
There are 4 clinical trials for lung carcinoid tumor, of which 3 are open and 1 is completed or closed. Of the trials that contain lung carcinoid tumor as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (2 open).
SSTR2, SSTR1, and SSTR3 are the most frequent gene inclusion criteria for lung carcinoid tumor clinical trials .
177lu-opsc001, cabozantinib, and everolimus are the most common interventions in lung carcinoid tumor clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.